June 6, 2023

AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals

AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals

LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) — AccuStemSciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated toimproving outcomes for patients with cancer, today announced the establishmentof a joint clinical collaboration agreement with University Hospitals.

Per the terms of this agreement, University Hospitals will provide tissue sampleswith clinical outcomes to AccuStem for research purposes. The scope of theagreement covers a multitude of different cancers but will initially focus on breastcancer cases to support further validation of the StemPrintER test. The goal of theinitial project is to build on the strong foundation of data for StemPrintER bydemonstrating additional clinical utility beyond identifying patients’ risk ofrecurrence. This next step is critical for women with early stage breast cancerbecause there are many tests to determine the need for chemotherapy but there areno genomic tools to inform decisions earlier in the continuum of care. StemPrintERmay be able to shift this paradigm by informing physicians of the most effectiveapproaches to surgical or radiological treatment.

“AccuStem has arrived at an important juncture as we progress towardcommercializing StemPrintER,” said Wendy Blosser, Chief Executive Officer ofAccuStem. “With this collaboration, we intend to expand beyond identifying apatient’s prognosis by addressing unanswered clinical questions and supportingsurgeons and radiation oncologists with their treatment planning.”

AccuStem and its clinical collaborators plan to present the data obtained under thisagreement at scientific conferences and to publish the findings in peer-reviewedmedical journals. Those activities will help to bolster the foundation of data forStemPrintER and familiarize physicians with its utility and value in clinical decisionmaking with the ultimate goal of improving patient outcomes and quality of life.

“We are excited to work with AccuStem on this clinical project,” said HannahGilmore, Division Chief, Anatomic Pathology, University Hospitals Cleveland MedicalCenter and Professor of Pathology, Case Western Reserve University. “I am veryinterested in the foundation for the StemPrintER test and think that it could haveimportant implications for treatment planning in breast cancer and perhaps manyother tumor types.”

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomesand quality of life for all patients with cancer. We plan to drive innovation inhealthcare by offering proprietary molecular testing that addresses unmet clinicalneeds from cancer screening through treatment and monitoring. By interrogatingnovel disease pathways, such as tumor “stemness”, we believe our tools will helpcare teams better understand the biology of each patient’s cancer, leading to moreinformed decision making. For more information, please visit www.accustem.com.

About University Hospitals / Cleveland, Ohio

Founded in 1866, University Hospitals serves the needs of patients through anintegrated network of 21 hospitals (including five joint ventures), more than 50health centers and outpatient facilities, and over 200 physician offices in 16 countiesthroughout northern Ohio. The system’s flagship quaternary care, academic medicalcenter, University Hospitals Cleveland Medical Center, is affiliated with Case WesternReserve University School of Medicine, Northeast Ohio Medical University, OxfordUniversity, the Technion Israel Institute of Technology and National Taiwan UniversityCollege of Medicine. The main campus also includes the UH Rainbow Babies &Children’s Hospital, ranked among the top children’s hospitals in the nation; UHMacDonald Women’s Hospital, Ohio’s only hospital for women; and UH SeidmanCancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH ishome to some of the most prestigious clinical and research programs in the nation,with more than 3,000 active clinical trials and research studies underway. UHCleveland Medical Center is perennially among the highest performers in nationalranking surveys, including “America’s Best Hospitals” from U.S. News & WorldReport. UH is also home to 19 Clinical Care Delivery and Research Institutes. UHis one of the largest employers in Northeast Ohio with more than 30,000 employees.Follow UH on LinkedIn, Facebook and Twitter. For more information,visit UHhospitals.org.

Forward-Looking Statements

This press release contains “forward-looking statements”. Forward-lookingstatements reflect our current view about future events. When used in this pressrelease, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us orour management, identify forward-looking statements. Such statements include,but are not limited to, statements contained in this press release relating to ourbusiness strategy, our future operating results and liquidity and capital resourcesoutlook. Forward-looking statements are based on our current expectations andassumptions regarding our business, the economy and other future conditions.Because forward–looking statements relate to the future, they are subject toinherent uncertainties, risks and changes in circumstances that are difficult topredict. Our actual results may differ materially from those contemplated by theforward-looking statements. They are neither statements of historical fact norguarantees of assurance of future performance. We caution you therefore againstrelying on any of these forward-looking statements. Important factors that couldcause actual results to differ materially from those in the forward-lookingstatements include, without limitation, our ability to raise capital to fund continuingoperations; our ability to protect our intellectual property rights; the impact of anyinfringement actions or other litigation brought against us; competition from otherproviders and products; our ability to develop and commercialize products andservices; changes in government regulation; our ability to complete capital raisingtransactions; and other factors relating to our industry, our operations and results ofoperations. Actual results may differ significantly from those anticipated, believed,estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from timeto time, and it is not possible for us to predict all of them. We cannot guaranteefuture results, levels of activity, performance or achievements. AccuStem Sciences,Inc. assumes no obligation to update any forward-looking statements in order toreflect any event or circumstance that may arise after the date of this release.

Media Contact:

Jeff FenstererEmail:

[email protected]

Investor Contact:

Wendy BlosserEmail:

[email protected]

Stay Informed

Our Technology

We are building an ecosystem of products that will change how cancer is treated and managed.